Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic ctDNA-Guided Adjuvant Therapy in Gastric or GEJ Adenocarcinoma
NCT07507916Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of serplulimab in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07507916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07507916.